AU2003248893A1 - Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias - Google Patents

Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Info

Publication number
AU2003248893A1
AU2003248893A1 AU2003248893A AU2003248893A AU2003248893A1 AU 2003248893 A1 AU2003248893 A1 AU 2003248893A1 AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A AU2003248893 A AU 2003248893A AU 2003248893 A1 AU2003248893 A1 AU 2003248893A1
Authority
AU
Australia
Prior art keywords
parkinson
disease
compositions
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003248893A
Other languages
English (en)
Other versions
AU2003248893A8 (en
Inventor
Jodi Nelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha Research Group LLC
Original Assignee
Alpha Research Group LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/192,414 external-priority patent/US20020198231A1/en
Application filed by Alpha Research Group LLC filed Critical Alpha Research Group LLC
Publication of AU2003248893A1 publication Critical patent/AU2003248893A1/en
Publication of AU2003248893A8 publication Critical patent/AU2003248893A8/xx
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2003248893A 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias Abandoned AU2003248893A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/192,414 US20020198231A1 (en) 1999-07-13 2002-07-09 Compositions and methods for the treatment of Parkinson's disease
US10/192,414 2002-07-09
US47974803P 2003-06-19 2003-06-19
US60/479,748 2003-06-19
PCT/US2003/021463 WO2004004660A2 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson’s disease and tardive dyskinesias

Publications (2)

Publication Number Publication Date
AU2003248893A1 true AU2003248893A1 (en) 2004-01-23
AU2003248893A8 AU2003248893A8 (en) 2004-01-23

Family

ID=30117814

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003248893A Abandoned AU2003248893A1 (en) 2002-07-09 2003-07-09 Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias

Country Status (5)

Country Link
EP (1) EP1581167A4 (https=)
JP (1) JP2006514917A (https=)
AU (1) AU2003248893A1 (https=)
CA (1) CA2531810A1 (https=)
WO (1) WO2004004660A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007067714A2 (en) 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
RU2008135762A (ru) * 2006-02-16 2010-03-27 Де МакЛин Хоспитал Корпорейшн (US) Способы и композиции для лечения болезни паркинсона
AU2010256541B2 (en) * 2009-06-03 2016-03-10 Marquette University Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof
CN103180297A (zh) * 2009-12-11 2013-06-26 基因密码公司 使用gdnf家族配体(gfl)模拟剂或ret信号传导通路活化剂促进神经细胞存活的方法
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2025213007A1 (en) * 2024-04-04 2025-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services S-hydroxychloroquine, optionally with tauroursodeoxycholic acid and/or 3,3'-diindolylmethane, for treating and/or preventing neurological disorders
CN119924299B (zh) * 2025-04-08 2025-06-06 内蒙古农业大学 羊精子内源铁死亡抑制蛋白保护剂及保护方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430039A (en) * 1990-09-28 1995-07-04 Cephalon, Inc. Treatment of neurological disorders
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders
DE4428199A1 (de) * 1994-08-09 1996-02-15 Univ Ludwigs Albert Verwendung von Flunitrazepam und/oder Chloroquin zur Behandlung von Spätdyskinesien
ATE431141T1 (de) * 1999-07-13 2009-05-15 Alpha Res Group Llc Zusammensetzungen und verfahren zur behandlung der parkinson-krankheit

Also Published As

Publication number Publication date
EP1581167A2 (en) 2005-10-05
EP1581167A4 (en) 2008-10-29
WO2004004660A2 (en) 2004-01-15
JP2006514917A (ja) 2006-05-18
CA2531810A1 (en) 2004-01-15
AU2003248893A8 (en) 2004-01-23
WO2004004660A3 (en) 2005-11-03

Similar Documents

Publication Publication Date Title
AU2003223579A1 (en) Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
EP1571968A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2003072035A8 (en) Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en) Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en) Compositions and methods for the treatment of immune related diseases
EP1572091A3 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004060270A8 (en) Compositions and methods for the diagnosis and treatment of tumor
TWI340640B (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
AU2003290548A1 (en) Prevention and treatment of synucleinopathic disease
AU2003224638A1 (en) PDPK1s AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
WO2003057160A8 (en) Compositions and methods for the diagnosis and treatment of tumor
PL371281A1 (en) Methods and compositions for the treatment of eye diseases
WO2005003154A8 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003237792A1 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2003254146A1 (en) Methods for the treatment of parkinson's disease
AU2003219160A1 (en) Methods and compositions for the treatment of cancer
AU2003248893A1 (en) Compositions and methods for the treatment of parkinson's disease and tardive dyskinesias
EP1576109A3 (en) Methods and compositions for categorizing patients
WO2004024076A8 (en) Novel compositions and methods for the treatment of immune related diseases
AU2003220026A1 (en) Methods and compositions for the treatment of ischemia
AU2003244455A1 (en) Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
AU2003275433A1 (en) Compositions and methods for treating pain

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase